Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Lung Cancer

• Publication date

  2007-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.LUNGCAN.2007.06.027PMID 17698241
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer Statistics, 2006

  2006cited by this paper
• Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer

  2005cited by this paper
• Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI).

  2003cited by this paper
• Novel doublets in extensive-stage small-cell lung cancer: a randomized phase II study of topotecan plus cisplatin or paclitaxel (CALGB 9430).

  2002cited by this paper
• Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.

  2002cited by this paper
• Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung carcinoma

  2002cited by this paper
• Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.

  2002cited by this paper
• Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group.

  2001cited by this paper
• Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study

  2001cited by this paper
• Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group.

  2001cited by this paper
• Combination of Cisplatin, Ifosfamide, and Irinotecan with rhG-CSF Support for the Treatment of Refractory or Relapsed Small-Cell Lung Cancer

  2000cited by this paper
• Predictive and prognostic factors in small cell lung cancer: current status.

  2000cited by this paper
• Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma.

  1999cited by this paper
• Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer.

  1998cited by this paper
• Improvement and plateau in survival of small-cell lung cancer since 1975: a population-based study.

  1998cited by this paper
• Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group.

  1998cited by this paper
• Paclitaxel, cisplatin and etoposide combination chemotherapy: a comparison of dose intensity in two multifractionated dose schemas.

  1998cited by this paper
• A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer.

  1998cited by this paper
• Small cell lung cancer: state-of-the-art therapy in 1996.

  1997cited by this paper
• Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan.

  1996cited by this paper
• Late recurrence of small-cell lung cancer: treatment and outcome.

  1996cited by this paper
• Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer :f a randomized phase III study

  1994cited by this paper
• Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials.

  1994cited by this paper
• High dose-intensity chemotherapy, with accelerated cyclophosphamide-doxorubicin-etoposide and granulocyte-macrophage colony stimulating factor, in the treatment of small cell lung cancer.

  1993cited by this paper
• CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.

  1992cited by this paper
• Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.

  1992influential reference
• Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer.

  1991cited by this paper
• Southwest oncology group

  1990cited by this paper
• Cisplatin and etoposide (VP‐16) as a single regimen for small cell lung cancer. A phase II trial

  1989cited by this paper
• First-line therapy with VP-16 and cisplatin for small-cell lung cancer.

  1986cited by this paper
• Randomized phase II clinical trials.

  1985cited by this paper
• VP-16 and cisplatin as first-line therapy for small-cell lung cancer.

  1985cited by this paper

• A Novel Combination Therapy of Cisplatin with a Molecular Promoter for Cancer Treatment

  2017cites this paper
• Chemotherapy-Induced Weakness and Fatigue in Skeletal Muscle: The Role of Oxidative Stress

  2011cites this paper
• Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study

  2010cites this paper
• Hypersensitivity Reactions Associated with Platinum Antineoplastic Agents: A Systematic Review

  2010cites this paper
• Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma

  2010cites this paper
• Effektivnost' i perenosimost' kombinatsiy aranozy s tsisplatinom i topotekanom v eksperimente

  2010cites this paper
• Therapy-induced toxicity of the lungs: an overview.

  2009cites this paper
• Developmental tumourigenesis: NCAM as a putative marker for the malignant renal stem/progenitor cell population

  2009cites this paper
• Extensive-stage small-cell lung cancer: evolution of systemic therapy and future directions.

  2008cites this paper